根瘟灵治疗猫瘟热

2000年元月以来,笔者应用湖北省天门市根瘟灵对猫瘟热进行试验性治疗,获得满意效果:共试治98例,治愈90例,8例晚期病例治疗无效死亡,治愈率达92%. 1 治疗方法早期病例:一般用根瘟灵1号、3号,每kg体重0.8ml分别肌注,每日一次,连续注射3次,即可痊愈.病程较长:为防止脱水,可用口服补液盐让病猫自由饮用;若体温偏高,应用根瘟灵治疗时,可配合先锋霉素胶囊口服,疗效更佳.严重病例:因呕吐或肠炎导致脱水,可用先锋霉素4号、维生素C、葡萄糖氯化钠注射液腹腔注射.呕吐者加维生素B6;肠炎腹泻者加入卡那霉素.多数病例腹腔注射后,病情迅速好转,具有立竿见影之效.恢复期病例:可给于营养易消化食物;食欲欠佳者,可用复合VB肌注.     

桂林老虎猫瘟热病毒的分离鉴定

我们在作猫细小病毒分子流行病学调查过程中,从桂林送棼的考虑粪便中分离出１株虎细小病毒,并对其进行了系统鉴定,经形态学理化学血清学交叉中和试验、动物感染试验与分子生物学,证明为一株猫瘟热病毒（猫泛白细胞减少症病毒）的强毒。     

猫疱疹病毒Ⅰ型荧光定量聚合酶链式反应检测方法的建立

研究旨在建立实时荧光定量聚合酶链式反应(real-time quantitative polymerase chain reaction,qPCR)检测猫疱疹病毒Ⅰ型(Feline herpesvirus type Ⅰ,FHV-1)的方法,用于检测临床上猫的上呼吸道传染病样本。据Gen Bank已发表的猫疱疹病毒的gE基因序列的保守区域设计并合成一对特异性引物及探针,建立FHV-1的实时荧光定量PCR检测方法,对此方法进行特异性、灵敏度及重复性的验证,并对广东佛山某流浪猫基地猫疱疹病毒的流行情况进行调查,即对该基地的94份临床样品进行检测。结果表明：研究成功建立了FHV-1实时荧光定量聚合酶链式反应检测方法,此方法特异性强,与大多流行的犬猫病毒均未出现交叉反应;敏感性高,最低检出限为10 copies·μL^-1;重复性好,批内变异系数为0.29%～0.71%,批间变异系数为0.88%～1.38%。应用此方法在94份临床样品中检出28份FHV-1核酸阳性样品。综上所述,研究建立的FHV-1荧光定量聚合酶链式反应方法具有较好的特异性、敏感性和重复性,为临床上FHV-1...     

中西结合治疗猫瘟热

中西结合治疗猫瘟热单守廪（山东省畜牧兽医总站，济南２５００２２）单令武（山东省宁阳县葛石镇兽医站，２７１４０４）单令文（山东省宁阳县石集镇兽医站，２７１４１７）聂克平（济南市奶牛一场，２５０３０６）单令旺（济南动物园，２５００３１）猫瘟热也称猫泛白细...     

猫瘟热的治疗

猫瘟热又叫猫传染性肠炎或猫泛白细胞减少综合症。是由猫细小病毒引起的猫的一种急性、高接触性、致死性传染病。临床上以高热呕吐、腹泻脱水和明显的白细胞数减少等为主要特征。本病常呈地方性流行 ,成为猫的主要传染病之一。且以幼猫发病较多。笔者从事宠物诊疗工作多年 ,治疗猫瘟热 10 0余例 ,效果良好 ,现简要介绍如下 :1　临床症状　病初精神沉郁 ,不食 ;体温上升至4 0℃以上 ,持续 2 4小时后下降至常温 ,2 - 3天后又上升到 4 0℃以上 ,呈双相热型。剧烈呕吐 ,初吐白沫样黏液 ,后吐黄绿色黏液。腹泻 ,拉水样带血稀便。由于呕吐和腹泻的…     

猫瘟热的综合诊治

猫瘟热又称猫泛白细胞减少症或猫传染性肠炎,多发生于冬末至春季,主要是幼猫的一种急性、高度接触性、发热性传染病.本病以体温升高、白细胞减少、呕吐和腹泻为特征.     

猫瘟热诊治

本病主要侵害猫科动物,如猫、豹、虎等,各龄猫对本病都易感,以幼猫,尤其是2~5 月龄的猫多发。导致发病的病原是猫泛白细胞减少症病毒,其属细小病毒科。该病传染性极高,以直接接触感染为主,也可经吸血虫类引起感染。病猫的呕吐物、唾液、尿、粪便和眼鼻分泌物中含有大量病毒,病毒可污染食物、食盆、猫舍及周围环境,使易感动物发病。     

用PCR法检测东北虎感染猫细小病毒的研究

根据GenBank中已发表的猫细小病毒基因组中的保守序列 ,利用Goldkey软件设计了一对能扩增 750bp片段大小的引物 ,对某动物园 1只病死东北虎的脾脏样品进行了PCR检测。结果得到了与设计大小完全相符且与标准猫细小病毒扩增产物大小一致的特异核酸带 ,同时对犬瘟热、犬腺病毒、轮状病毒的核酸扩增结果均为阴性。敏感性试验表明 ,此法可检出血凝价为 1 2 8×脾脏匀浆液上清 1 0 - 5倍稀释的模板 ,远高于血凝试验的敏感性 ,为虎、狮、熊猫等野生动物细小病毒病的快速诊断提供了一个有效的方法     

Dog response to inactivated canine parvovirus and feline panleukopenia virus vaccines

Inactivated canine parvovirus (CPV) and inactivated feline panleukopenia virus (FPV) vaccines were evaluated in dogs. Maximal serologic response occurred within 1-2 weeks after vaccination. Antibody titers then declined rapidly to low levels that persisted at least 20 weeks. Immunity to CPV, defined as complete resistance to infection, was correlated with serum antibody titer and did not persist longer than 6 weeks after vaccination with inactivated virus. However, protection against generalized infection was demonstrated 20 weeks after vaccination. In unvaccinated dogs, viremia and generalized infection occurred after oronasal challenge with virulent CPV. In contrast, viral replication was restricted to the intestinal tract and gut-associated lymphoid tissue of vaccinated dogs. Canine parvovirus was inactivated by formalin, beta-propiolactone (BPL), and binary ethylenimine (BEI) in serum-free media; inactivation kinetics were determined. Formalin resulted in a greater loss of viral HA than either BEI of BPL, and antigenicity was correspondingly reduced.     

Three-year duration of immunity in cats following vaccination against feline rhinotracheitis virus, feline calicivirus, and feline panleukopenia virus

Forty-two seronegative cats received an initial vaccination at 8 weeks of age and a booster vaccination at 12 weeks. All cats were kept in strict isolation for 3 years after the second vaccination and then were challenged with feline calicivirus (FCV) or sequentially challenged with feline rhinotracheitis virus (FRV) followed by feline panleukopenia virus (FPV). For each viral challenge, a separate group of 10 age-matched, nonvaccinated control cats was also challenged. Vaccinated cats showed a statistically significant reduction in virulent FRV-associated clinical signs (P = .015), 100% protection against oral ulcerations associated with FCV infection (P < .001), and 100% protection against disease associated with virulent FPV challenge (P < .005). These results demonstrated that the vaccine provided protection against virulent FRV, FCV, and FPV challenge in cats 8 weeks of age or older for a minimum of 3 years following second vaccination.